Skip to main content
Log in

Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma

  • Special Issue - Original Article
  • Published:
Medical & Biological Engineering & Computing Aims and scope Submit manuscript

Abstract

In recent years, many local ablation technologies based on thermal damage have been used in the treatment of locally advanced pancreatic carcinoma (LAPC) and borderline resectable pancreatic carcinoma (BLRPC). However, they are associated with major complications because of possible vascular and ductal damage. Irreversible electroporation (IRE) is a nonthermal ablation technology that seems safe near vital vascular and ductal structures. IRE could be used as exclusive treatment of LAPC (en situ to IRE) after induction chemotherapy In BLRPC, surgery is not really radical in 6% of patients (microscopic residual) and local recurrences occur in 11–42% of apparent radical resections. IRE could be used as margin accentuation to increase posterior margin during radical surgery in BLRPC. Our outcomes are safety, time to progression. Secondary outcomes are overall survival, pain control and quality of life. We are performing a prospective evaluation of patients undergoing IRE for LAPC or BLRPC since July 2014. We have included patients with non-metastatic LAPC with maximum size ≤4 cm (en situ to IRE) and patients with BLRPC (complementary IRE). We have performed induction chemotherapy in both groups. After treatment, patients were evaluated on days 1, 2, 4, 7, 14, 21, 30, 60 and 90 with amylase and lipase serum and abdominal drainage test. Based on Ethics Committee’s request, follow-up imaging was performed at the 10th day for safety evaluation, at 30, 60 and 90 days for response evaluation and then every 3 months. Seven patients (two women and five men) underwent IRE. Two patients had LAPC and received en situ to IRE. In five patients affected by BLRPC we performed IRE and pancreatic head resection. In all patients, intraoperative imaging confirmed that the treatment of the whole tumor volume was complete. All seven patients demonstrated nonclinically relevant elevation of their amylase and lipase, which returned normal at 5 days postprocedure. No patient showed evidence of clinical pancreatitis or fistula. No major complications were recorded. Patients with LAPC died of distant metastases 6 month after treatment. At 3- and 6-month follow-up, all patients with BLPRC were alive and disease free. Only one patient has already reached 9-month follow-up and is alive and disease free. Our results are only preliminary. However, IRE ablation of LAPC and BLRPC seems a safe and feasible treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. AIRTUM Working group: i numeri del cancro in Italia 2013: Pancreas esocrino, 93–96, 2013

  2. Au JT, Mittra A, Song TJ, Cavnar M, Jun K, Carson J, Gholami S, Haddad D, Gaujoux S, Monette S, Ezell P, Wolchok J, Fong Y (2013) Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response. Surgery 154(3):496–503

    Article  PubMed  PubMed Central  Google Scholar 

  3. Bower et al (2011) Irreversible electroporation of the pancreas: definitive local therapies without systemic effects. J Surg Oncol 104(1):22–28

    Article  PubMed  Google Scholar 

  4. Cantore M et al (2012) Combined modality treatment for patient with locally advanced pancreatic cancer. Br J Surg 99:1083–1088

    Article  CAS  PubMed  Google Scholar 

  5. Cotsoglou C, Bongini M, Mazzaferro V (2014) Resecabilità e spazi di trattamento integrato nel carcinoma del pancreas localmente avanzato Professione Chirurgo; Anno II, Numero 3: luglio-settembre 2014

  6. Girelli R et al (2010) Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg 97:220–225

    Article  CAS  PubMed  Google Scholar 

  7. Gudjonsson B (1987) Cancer of the pancreas. 50 years of surgery. Cancer 60:2284–2303

    Article  CAS  PubMed  Google Scholar 

  8. Hammel P, Huguet F, Van Laethem J et al (2013) Randomized multicenter phase II study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib-LAP 07 study. ASCO Meeting Abstr 29:e14619

    Google Scholar 

  9. Huguet F, Mukherjee S, Javle M (2014) Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. Clin Oncol 26:560–568

    Article  CAS  Google Scholar 

  10. Kingham TP, Karkar AM, D’Angelica MI, Allen PJ, Dematteo RP, Getrajdman GI, Sofocleous CT, Solomon SB, Jarnagin WR, Fong Y (2012) Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 215(3):379–387

    Article  PubMed  Google Scholar 

  11. Kwon D, McFarland K, Velanovich V, Martin RC 2nd (2014) Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Surgery 156(4):910–920

    Article  PubMed  Google Scholar 

  12. Linee guida AIOM 2013 sul tumore del pancreas esocrino

  13. Maor E, Ivorra A, Leor J, Rubinsky B (2007) The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat 6(4):307–312

    Article  PubMed  Google Scholar 

  14. Martin RC 2nd, McFarland K, Ellis S, Velanovich V (2012) Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg 215(3):361–369

    Article  PubMed  Google Scholar 

  15. Martin RC 2nd, McFarland K, Ellis S, Velanovich V (2013) Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol 20(Suppl 3):S443–S449

    Article  PubMed  Google Scholar 

  16. Martin RC 2nd, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, McMasters KM, Watkins K (2015) Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg 262(3):486–494

    Article  Google Scholar 

  17. Moir J, White SA, French JJ, Littler P, Manas DM (2014) Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer. Eur J Surg Oncol 40(12):1598–1604. doi:10.1016/j.ejso.2014.08.480

    Article  CAS  PubMed  Google Scholar 

  18. NCCN guidelines Version 2.2014 (2014) Pancreatic Adenocarcinoma Ago, pp 1–142

  19. StatBite (2010) U.S. pancreatic cancer rates. J Natl Cancer Inst 102:1822

    Article  Google Scholar 

  20. Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P (2008) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 99(1):6–13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Worni M, Guller U, White RR et al (2013) Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas 42:1157–1163

    Article  PubMed  Google Scholar 

  22. Yeo TP, Hruban RH, Leach SD et al (2002) pancreatic cancer. Curr Probl Cancer 26:176–275

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Founded by “FPRC (ONLUS) fondi 5 mille 2012 Ministero della Salute.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. De Simone.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marsanic, P., Mellano, A., Sottile, A. et al. Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma. Med Biol Eng Comput 55, 1123–1127 (2017). https://doi.org/10.1007/s11517-016-1603-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11517-016-1603-9

Keywords

Navigation